Melbourne, Australia and Nantes, France, Jan. 18, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS (Atlab). Under the terms of the agreement, Telix will finance the manufacturing and clinical development of the huJ591 monoclonal antibody (mAb) radiolabelled with 177Lu (Lutetium) and 211At (Astatine), both promising theranostic products for the treatment of metastatic prostate cancer. The huJ591 mAb was originally developed by Dr. Neil Bander at the Weill Cornell Graduate School of Medical Sciences (New York, NY) and targets Prostate-Specific Membrane Antigen (PSMA), a well-validated target in prostate cancer. The full press release can be found here.